# COMPANION-002 (NCT05506943)

> A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05506943
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Compass Therapeutics
- Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer; Ampullary Cancer
- Interventions: CTX-009; Paclitaxel
- Enrollment: 168
- Primary outcome: Best Overall Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=companion-002-nct05506943

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05506943", "email": "<work email>"}; the inbox owner confirms by the emailed link.